Oryzon Genomics (XMAD:ORY) Ending Cash Position : €0.00 Mil (As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Oryzon Genomics Ending Cash Position?

Oryzon Genomics's Ending Cash Position for the quarter that ended in Sep. 2024 was €0.00 Mil.

Oryzon Genomics's annual Ending Cash Position declined from Dec. 2021 (€28.73 Mil) to Dec. 2022 (€21.32 Mil) and declined from Dec. 2022 (€21.32 Mil) to Dec. 2023 (€12.26 Mil).

Oryzon Genomics Ending Cash Position Historical Data

The historical data trend for Oryzon Genomics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oryzon Genomics Ending Cash Position Chart

Oryzon Genomics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

35.11

39.61

28.73

21.32

12.26

Oryzon Genomics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Ending Cash Position	Get a 7-Day Free Trial															-	-	-	-	-

Oryzon Genomics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Oryzon Genomics's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	21.318	+	-9.061
	=	12.26

Oryzon Genomics's Ending Cash Position for the quarter that ended in Sep. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	0	+	0
	=	0.00

Oryzon Genomics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Oryzon Genomics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Oryzon Genomics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oryzon Genomics SA (XMAD:ORY) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

ORYZF:USA ORYe:UK 0RDB:UK ORN:Germany

Address

Sant Ferran 74, Cornellà de Llobregat, Barcelona, ESP, 08940

Website

http://www.oryzon.com

Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.

Oryzon Genomics Headlines

No Headlines